Clinical Trial: A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Safety and Efficacy of A-60444 in Adults With RSV Infection Following Stem Cell Transplantation

Brief Summary:

Objectives

Primary Objectives:

  • Pilot Study: A preliminary assessment of the exposure and safety of oral A-60444 in post-stem cell transplant patients with RSV infection.
  • Main Study: To determine the antiviral effect of oral A-60444 versus placebo in post-stem cell transplant patients with RSV infection and to assess the safety of oral A-60444 in post-stem cell transplant patients with RSV infection.

Secondary Objectives:

  • To study the pharmacokinetics of A-60444 in the presence of concomitant medications such as immunosuppressants and antifungals, in post-stem cell transplant patients with RSV infection.

Sample Size: Six patients will be included in the open, pilot phase of the study and there is an option to include a further 22 patients into the main, placebo-controlled study, depending on the pilot study findings. An independent Data Safety Monitoring Board will assess the findings of the pilot study.


Detailed Summary: Clinical will be recorded daily. A-60444 PK will be studied pre-dose and at peak dose on the last day (Day 5) of dosing.
Sponsor: Arrow Therapeutics

Current Primary Outcome:

  • Reduction of viral load over time:
  • 2-log reduction (by quantitative real time reverse transcription polymerase chain reaction [rtRT PCR]) in the RSV load of nasopharyngeal swabs in patients three days after treatment with A-60444, compared to patients treated with placebo


Original Primary Outcome:

  • Reduction of viral load over time:
  • 2-log reduction (by quantitative real time reverse transcription polymerase chain reaction [rtRT PCR]) in the RSV load of nasopharyngeal swab in patients three days after treatment with A-60444, compared to patients treated with placebo.


Current Secondary Outcome:

  • Change in viral titre over treatment period
  • Safety, pharmacokinetics (PK)


Original Secondary Outcome:

  • Change in viral titre over treatment period
  • Safety, PK.


Information By: Arrow Therapeutics

Dates:
Date Received: October 4, 2005
Date Started: September 2005
Date Completion:
Last Updated: February 11, 2010
Last Verified: February 2010